pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
26d
Recon: FDA approves Edwards’ tricuspid valve repair device; Bayer wins Chinese approval for blood thinner asundexian
raps
26d
#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
endpoints
27d
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
fiercebiotech
27d
STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
stat
27d
Tonight We Ride, LLC Issues Voluntary Recall of Ultimate Forza Male Supplement Due to Presence of Undeclared Sildenafil, Tadalafil, and Dapoxetine
fda recalls
28d
Opinion: STAT readers on Elizabeth Holmes, cancer screening, and more
stat
28d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
28d
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
biospace
28d
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
biospace
28d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
29d
Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
fiercebiotech
29d
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
29d
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
29d
This Week at FDA: Peptide dispute, clinical trial legislation, and more
raps
29d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
29d
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
biospace
29d
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
biopharma dive
29d
Chutes & Ladders—Troubled CSL enlists GSK vet Deborah Waterhouse to lead
fiercebiotech
29d
Roche says it will help patients who are 'anxiously awaiting' its new breast cancer drug
endpoints
29d
Biohaven’s previously rejected rare disease drug to get fresh FDA review
biopharma dive
29d
STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
stat
29d
Roche affirms sales outlook amid doubts about its future
biopharma dive
29d
A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approval
endpoints
29d
STAT+: Crackdowns loom, from China to New York
stat
29d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
29d
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
stat
Oct 22, 26
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
Oct 22, 26
ESMO: Zentalis already dreaming of launch for WEE1 inhibitor after ‘great result’ in early-stage test
fiercebiotech
Oct 22, 26
AbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations
fiercebiotech
Oct 22, 26
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
← prev
page 10 of 52
next →